Historical comparisons are misleading for the last few years, because Abraxane revenue slipped when they took the sales in-house away from AZN. Current quarter over last year's quarter, the growth was around 25% ($88m vs $70m), and pre-merger that was about the annual growth rate that analysts were estimating.
Market Data 
Markets 
AI
